Table1_难治性心绞痛患者中Neovasc Reducer装置的预算影响模型与成本-效用分析.docx

数据集获取（Figshare）

• 源站标题：Table1_A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina.docx
• DOI：10.3389/fcvm.2024.1307534.s001
• 发布日期：2024-03-18
• 文件数：1 个
• 文件总体积：32.63 KB
• 源站页面：https://frontiersin.figshare.com/articles/dataset/Table1_A_budget_impact_model_and_a_cost_utility_analysis_of_reducer_device_Neovasc_in_patients_with_refractory_angina_docx/25426870

命令行下载

curl -L -o "Table1_A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina.docx" "https://ndownloader.figshare.com/files/45102085"

文件清单

• Table1_A budget impact model and a cost–utility analysis of reducer device (Neovasc) in patients with refractory angina.docx（32.63 KB）

文件总体积 32.63 KB（源站 API 实测）。

数据加载示例（图像类）

from PIL import Image
import glob, os

files = (glob.glob(os.path.join(path, "**", "*.png"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.jpg"), recursive=True)
       + glob.glob(os.path.join(path, "**", "*.tif"), recursive=True))
print("图像文件数:", len(files))
img = Image.open(files[0]); print("尺寸/模式:", img.size, img.mode)

# torchvision Dataset 方式:
# from torchvision import datasets
# ds = datasets.ImageFolder(path)  # 要求 子目录=类别

目录组织与标注格式以源站说明和下载后实际文件为准。

数据说明

BackgroundRefractory angina (RA) is a chronic condition characterized by the presence of debilitating angina symptoms due to established reversible ischemia in the presence of obstructive coronary artery disease (CAD). Treatments for this condition have undergone major developments in recent decades; however, the treatment for RA remains a challenge for medicine. In this sense, the Coronary Sinus Reducer System (CSRS) stands as the last line of therapy for ineligible patients for revascularization with reversible ischemia. The purpose of this report is to evaluate the potential burden on the National Health Service (NHS) and measure the health effects in terms of both quantity (life years) and quality-of-life aspects related to the reducer.
MethodsTwo different economic evaluation models were developed as part of the analysis. The budget impact was developed to estimate the potential burden on the NHS from incremental uptake of the use of the reducer in the target population. The utility cost analysis compares and evaluates the quality of life and health resource use and costs between the two alternatives, based on the research of Gallone et al. A deterministic and probabilistic sensitivity analysis was carried out to characterize the uncertainty around the parameters of the model.
ResultsIn the budget impact analysis (BIA), the reducer is shown to be more expensive in the first 2 years of the model, due to the gradual uptake in the market and the cost of the device. Starting from the third year, assuming maintenance of effectiveness, there are savings in terms of resource absorption in direct healthcare costs arising from hospitalizations, emergency department accesses, coronarography, and visits avoided.
ConclusionThe BIA and cost-effectiveness model show that the reducer device, despite an increase in resources absorbed in the first years of implementation and use, has the potential to result in increased quality of life in patients with RA. These costs are largely offset in the short term by the improved clinical outcomes achievable leading to savings from the third year onward in the BIA and a dominance ratio in the cost–utility analysis.

许可

CC BY 4.0

引用

学术使用请引用 DOI 10.3389/fcvm.2024.1307534.s001（source: https://frontiersin.figshare.com/articles/dataset/Table1_A_budget_impact_model_and_a_cost_utility_analysis_of_reducer_device_Neovasc_in_patients_with_refractory_angina_docx/25426870）。